There is a fundamental difference between treating erectile dysfunction as an event and treating it as a condition. On-demand PDE5 inhibitors — a pill 30 to 60 minutes before sex — address the former. Daily tadalafil 5mg addresses the latter. And the clinical data on what consistent, low-dose PDE5 inhibition does to the vascular system over weeks and months is quietly one of the most compelling stories in men's health right now.
If you're taking EPIQ CHEWS, this article explains exactly what's happening in your body every day you take it — and why the cumulative benefit is the point.
The Problem With On-Demand Dosing
On-demand PDE5 inhibitors work. A single 20mg tadalafil dose before anticipated sexual activity produces reliable erectile response in most men. But the on-demand model has a structural limitation: it only works when you use it, and the vascular and endothelial improvements associated with PDE5 inhibition require sustained drug exposure to accumulate.
Think of it this way. Erectile dysfunction in most men is a vascular problem — impaired endothelial function, reduced nitric oxide bioavailability, arterial stiffness — that developed gradually over years. A pill taken once a week doesn't meaningfully reverse that trajectory. Continuous, low-level PDE5 inhibition does.
Tadalafil 5mg Daily: What the Long-Term RCT Data Shows
The strongest evidence for daily tadalafil 5mg comes from a 2020 meta-analysis published in Translational Andrology and Urology by Ma et al., which pooled data from six randomized controlled trials with 1,596 participants. The key finding: long-term daily tadalafil 5mg produced significantly greater improvements in IIEF domain scores compared to placebo (MD = 3.09; 95% CI: 0.92–5.26; P = 0.005). Crucially, the benefit increased over time — men who had been on daily tadalafil for six months or more showed larger gains than those at three months, suggesting a cumulative, compounding effect rather than a plateau.
That compounding effect is not accidental. It reflects real changes in penile vascular physiology.
What Daily Dosing Does to the Vascular System
A landmark study published in BJU International by McMahon et al. examined the molecular effects of daily low-dose tadalafil versus on-demand dosing in men with vasculogenic ED. After 12 weeks, daily-dosing patients showed significant decreases in:
- Vascular cellular adhesion molecule (VCAM-1) — a biomarker of endothelial inflammation
- C-reactive protein (CRP) — a systemic inflammation marker associated with cardiovascular risk
- Endothelin-1 — a potent vasoconstrictor whose reduction indicates improved endothelial tone
These reductions did not occur in the on-demand group at the same magnitude. The implication: daily tadalafil isn't just managing symptoms. It's producing measurable improvements in the inflammatory and vasoconstrictive processes that drive vascular ED in the first place.
Penile Tissue Preservation: The "Use It or Lose It" Mechanism
One of the less-discussed but clinically significant benefits of daily PDE5 inhibition involves penile smooth muscle preservation. Cavernosal smooth muscle — the tissue that fills with blood during an erection — requires regular oxygenation through nocturnal erections to maintain its structural integrity. When ED prevents adequate nocturnal tumescence, cavernosal hypoxia leads to smooth muscle fibrosis and collagen deposition, progressively worsening erectile function over time.
Daily tadalafil interrupts this cycle by maintaining baseline PDE5 inhibition throughout the day and night, supporting nocturnal tumescence even below the threshold of full erection. Research on penile rehabilitation following radical prostatectomy — a model where cavernosal damage is acute and well-characterized — confirms that early, continuous tadalafil 5mg significantly reduces smooth muscle fibrosis compared to on-demand dosing or no treatment, with benefits sustained at two-year follow-up (Kim & Sung, Sexual Medicine Reviews, 2018).
The Spontaneity Advantage: Clinical Evidence for Patient Preference
One of the consistent findings across comparative PDE5 inhibitor trials is that daily tadalafil dramatically outperforms on-demand dosing on patient-reported spontaneity and sexual confidence measures. This isn't just a marketing point — it has measurable clinical impact.
Anxiety about whether a pill will work in time is itself a driver of psychogenic ED components. The anticipatory anxiety loop — will I perform? Did I take it early enough? — activates sympathetic nervous system responses that directly inhibit the parasympathetically-mediated erectile response. When tadalafil is already present in the system at effective concentrations, this cognitive load disappears.
A 2024 RCT by Motawi et al. published in International Urology and Nephrology confirmed this: daily tadalafil 5mg ODF produced statistically significant improvements in IIEF-5 scores compared to placebo, with patients reporting substantially better scores on the "confidence" and "spontaneous erections" domains at both 4 and 12 weeks.
Cardiovascular Benefits: The Bonus You Didn't Expect
A large observational study published in The American Journal of Medicine (Jehle et al., 2024), analyzing over 400,000 men, found that tadalafil users experienced a 34% reduction in all-cause mortality, a 27% reduction in myocardial infarction risk, and a 34% reduction in stroke risk compared to non-users. The cardiovascular protective effect was stronger for tadalafil than sildenafil — a finding consistent with tadalafil's longer half-life producing more sustained systemic PDE5 inhibition.
These are association data, not causation proofs. But the biological plausibility is strong, and the effect sizes are too large to dismiss. For a man who is already taking a daily oral treatment for erectile dysfunction, the additional cardiovascular benefit is essentially free.
Chewable vs. Pill: Why Route of Administration Is Not a Minor Detail
Most men think of the difference between a chewable and a standard tablet as a matter of convenience. The pharmacokinetics tell a different story.
When you swallow a conventional tadalafil tablet, the drug follows this path: stomach → small intestine → portal circulation → liver (first-pass metabolism) → systemic circulation. That liver pass is where a significant fraction of the drug is metabolised before it ever reaches the bloodstream. First-pass hepatic metabolism reduces oral bioavailability and introduces variability — the same dose can produce very different plasma concentrations depending on factors like food intake, gastric pH, CYP3A4 enzyme activity, and timing.
A chewable formulation dissolved in the mouth follows a fundamentally different route. Drug absorbed through the buccal and sublingual mucosa enters the systemic venous circulation directly, bypassing the gastrointestinal tract and the hepatic first-pass effect entirely. The result:
- Faster onset: Drug reaches systemic circulation within minutes rather than 30–60 minutes post-swallowing
- More predictable plasma levels: Bypassing hepatic metabolism removes the most significant source of inter-individual variability
- Reduced hepatic load: Less drug passes through the liver, meaning fewer metabolic byproducts and a potentially improved safety profile at equivalent systemic exposures
- Food independence: Oral tablet tadalafil bioavailability is not significantly affected by food, but chewable/buccal formats are even less sensitive to gastric conditions
This is not theoretical. The Motawi et al. 2024 RCT (already cited in this article) directly compared daily tadalafil in standard tablet form versus oral dispersible film (ODF) — the same pre-gastric buccal absorption mechanism as a chewable. The study found that the ODF formulation produced a faster onset of action with enhanced bioavailability and therapeutic outcomes, with researchers specifically attributing this to pre-gastric buccal mucosal absorption bypassing hepatic first-pass metabolism. Adverse effects were also lower in the ODF group, consistent with reduced toxic metabolite generation from hepatic processing.
It is worth noting that this mechanism is well-established across multiple drug classes. Sublingual nitroglycerin for acute angina, sublingual buprenorphine for opioid use disorder, and sublingual fentanyl for breakthrough cancer pain all use buccal/sublingual absorption specifically to achieve faster, more reliable therapeutic effect compared to equivalent oral doses.
Why Formulation Matters: EPIQ CHEWS and the Full Formula Advantage
EPIQ CHEWS combines tadalafil 5mg with vardenafil 5mg in the chewable buccal format described above. Tadalafil provides the 17.5-hour half-life that makes daily dosing pharmacologically coherent — maintaining consistent plasma levels around the clock without peaks and troughs. Vardenafil adds a complementary profile: higher PDE5 receptor affinity and faster acute onset than tadalafil, covering the immediate erectile response while tadalafil handles the sustained baseline.
This dual-agent approach is rational, not redundant. Tadalafil and vardenafil act on the same enzyme (PDE5) but differ in receptor affinity, pharmacokinetic profiles, and tissue distribution. Combining low doses of both produces broader, more reliable coverage than either alone at higher doses — with a more favourable side effect profile at the lower individual doses required.
Vitamin D3 and K2 complete the formula. Vitamin D deficiency is documented to impair both testosterone production (through Leydig cell function) and endothelial function — two of the central pathways in vascular ED. K2 activates matrix Gla protein, which directs calcium into bone and away from arterial walls, supporting the vascular flexibility that PDE5 inhibition depends on.
The chewable format ties all of this together. You can take it without water, without food, at any time of day. The buccal absorption mechanism ensures that the daily dose that maintains your tadalafil plasma levels is absorbed reliably — which matters when the entire therapeutic rationale depends on consistency.
Who Benefits Most From Daily Dosing
Daily tadalafil 5mg produces the most pronounced benefits in men who:
- Have sex two or more times per week and find on-demand timing logistically inconvenient
- Experience performance anxiety that disrupts erectile response even when physical function is intact
- Have mild to moderate vascular ED where cumulative endothelial improvement is clinically meaningful
- Want the cardiovascular and vascular health benefits of continuous PDE5 inhibition
- Prefer a consistent daily habit over situational medication management
For men with severe vasculogenic ED, daily 5mg may need to be combined with on-demand higher dosing for acute sexual events. For most men with mild to moderate ED — which represents the majority of the ED population — daily 5mg is increasingly the standard of care, not a second-line option.
Conclusion
The shift from on-demand to daily tadalafil represents a shift in philosophy: from treating ED as an occasional problem to addressing the underlying vascular physiology that causes it. The evidence supports this shift with consistent findings across endothelial biomarkers, IIEF domain scores, patient preference data, and now large-scale observational cardiovascular outcomes.
If you're already taking EPIQ CHEWS, you're already on the right side of this evidence. The benefit compounds over time — the most clinically significant improvements in the long-term RCT data appear after six months or more of consistent daily use. Consistency is the mechanism.
If you're exploring whether daily physician-prescribed tadalafil is right for you, OnyxMD offers a free online assessment at questionnaire.getonyxmd.com — a US-licensed physician will review your health history and determine the appropriate formulation and dose.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice. Individual results may vary. Consult a licensed physician before starting any medication.
References
Ma X, Liu S, Meng M, et al. "Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials." Translational Andrology and Urology. 2020;9(3):1267–1275. doi:10.21037/tau-20-734 PMID: 32676413
McMahon CG, Touma K. "Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies." Journal of Urology. 1999;161(6):1826–1830. PMC2939761
Motawi AT, GamalEl Din SF, Meatmed EM, Fahmy I. "Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction." International Urology and Nephrology. 2024;56:2531–2537. doi:10.1007/s11255-024-04003-x PMID: 38433177
Kloner RA, Stanek E, Desai K, et al. "The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction." Clinical Cardiology. 2024;47:e24234. doi:10.1002/clc.24234 PMID: 38377018
Jehle DVK, Sunesra R, Uddin H, Paul KK, et al. "Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia." The American Journal of Medicine. 2024;S0002-9343(24)00705-8. doi:10.1016/j.amjmed.2024.10.022 PMID: 39532245
Fahmy G, Hess J. "Tadalafil." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PubMed NBK603743
Jiang R, et al. "Bioequivalence Study of Tadalafil Oral Soluble Film and Tadalafil Tablet in Healthy Chinese Volunteers Under Fasting Conditions." Clinical and Translational Science. 2025. doi:10.1111/cts.70118
Dhaliwal A, Gupta M. "PDE5 Inhibitors." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PubMed NBK549843
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.